In light of a recent Lancet Global Health study highlighting substandard anti-cancer medications in several Sub-Saharan African countries, the South African Health Products Regulatory Authority (SAHPRA) has confirmed that South Africa is not affected. The study, which investigated the quality of specific cancer drugs in countries such as Ethiopia, Kenya, Malawi, and Cameroon, did not include South Africa in its sample. Furthermore, the brands identified in the report are neither registered nor marketed within the country.
SAHPRA has taken proactive steps to verify the safety and quality of cancer medications available in South Africa. After a thorough internal review and ongoing post-market surveillance, the authority confirmed that all locally registered and marketed anti-cancer drugs meet stringent regulatory requirements for quality, safety, and efficacy. Patients and healthcare providers can be assured that cancer treatments in South Africa remain uncompromised.
This commitment is aligned with SAHPRA’s mandate to uphold the highest standards in health product regulation, reaffirming its dedication to protecting the well-being of all South Africans.